Genentech, A Member of the Roche Group

Genentech, A Member of the Roche Group
Share
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture, and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

Second positive Phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the risk of tumor spread or growth in the brain or central nervous system Data will be simultaneously published in the New England Journal of Medicine and featured in the official ASCO press...

Actemra® is the first FDA-approved treatment for adults with giant cell arteritis (GCA) FDA previously granted Priority Review and Breakthrough Therapy Designation for Actemra in GCA Sixth FDA approval for Actemra since its U.S. launch in 2010 South San Francisco, CA -- May 22, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:...

OCREVUS rapidly suppressed signs of disease activity in relapsing MS (RMS) patients In patients with early RMS – recently diagnosed and without prior treatment – OCREVUS was superior to Rebif® (interferon beta-1a) in controlling disease activity OCREVUS decreased fatigue versus placebo in people with primary progressive multiple sclerosis (PPMS) In...

Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive...

First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) granted accelerated...

First and only medicine FDA-approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study South San Francisco, CA -- April 17, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),...

On April 17, 2017, the FDA granted approval to Lucentis® (ranibizumab injection) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. With this approval, Lucentis becomes the first and only FDA-approved medicine to treat diabetic retinopathy in people who have been diagnosed either with or without diabetic macular edema (DME), a...

On April 17, the FDA granted accelerated approval to TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. TECENTRIQ was previously approved for people with locally advanced or mUC who have disease progression during or following any...

Emicizumab prophylaxis reduced the number of bleeds in children with hemophilia A and inhibitors to factor VIII Results build upon data for emicizumab in adults and adolescents with hemophilia A and inhibitors to factor VIII South San Francisco, CA -- April 16, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today...

Second Phase III head-to-head study that showed that Alecensa helped people with advanced ALK-positive non-small cell lung cancer (NSCLC) Results showed that people treated with Alecensa lived significantly longer without their disease progressing compared to crizotinib when given as initial (first-line) treatment Data will be submitted to global...